Orbis Research Present’s Global Assisted Reproductive Technology Market 2017-2021 which Examine into the present trends, highlights the recent market growth, sales volume, Demand Scenarios and Opportunities emerging for business players in the near future.
Latest Research Report – Global Assisted Reproductive Technology Market 2017-2021
the following companies as the key players in the Global Assisted Reproductive Technology Market: Vitrolife, Ferring Pharmaceuticals, Irvine Scientific, and Cook Medical.
Other Prominent Vendors in the market are: CellCura, EMD Serono, Esco Micro, IKS International (Gonagen Medikal), INVO Bioscience, IVFtech, CRITEX (MedITEX), Pantec Biosolutions, Research Instruments, and Smiths Medical.
Commenting on the report: “The latest trend gaining momentum in the market is increasing number of single-parent families. In the last few years, the number of single women using fertility clinics had doubled since the start of the decade. The large majority of single parents are either divorced or separated, widowed, or not been married. This trend of single parent families is gaining traction due to social acceptance. One major reason is that there has been a notable increase in divorces in developed countries such as the US resulting in an increased number of single parent families.”
According to the report, one of the major drivers for this market is increase in awareness of ART. There is a notable increase in awareness of ART procedures among women compared with the last decade. This nurtured a positive attitude and acceptance among women worldwide. The increase in awareness can be attributed to several factors such as the rise in education level among the female population and the rise in the number of working women.
Get a PDF Sample of Global Assisted Reproductive Technology Market Report at: http://www.orbisresearch.com/contacts/request-sample/244569
Further, the report states that one of the major factors hindering the growth of this market is lack of strict regulatory oversight and limited reimbursements. Infertility treatment is considered a lifestyle procedure rather than serious medicine. Health insurance plans commonly, but not always, pay for services related to testing for infertility. For instance, in the US, which does not have any infertility coverage mandate, most insurance policies do not cover fertility and IVF service payment.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.